Kornimate/medical-research-clean huggingface dataset:
differentiation between healthy cerebral tissue and tumor tissue using a tissue sensing instrument

Conditions: Glioblastoma; Surgical Margin

Summary: differentiation between glioma tumor tissue and normal cerebral tissue using diffuse reflectance spectroscopy (drs) on surgical tissue samples ex-vivo

background: diffuse reflectance spectroscopy is an optically based technique which measures the amount of diffusely reflected light after it has undergone multiple scattering and absorption events within the tissue. each drs spectrum therefore has a specific 'optical fingerprint' reflecting the composition and morphology of the tissue within the probing volume. the technology is easily built into very small instruments that can be fused with regularly used surgical equipment. drs has previously been widely investigated for the purpose of margin assessment in other regions of the body. aim \& hypothesis: the primary goal is to show the feasibility of applying optical tissue sensing using diffuse reflectance spectroscopy (drs) to differentiate healthy cerebral tissue from tumorous tissue in ex vivo human tissue samples. this will be a basis for further development of surgical equipment able to identify the margin between healthy brain tissue and tumor tissue intraoperatively. method: using drs we aim to determine spectroscopy thresholds that enables differentiation of cerebral tissue from different forms of tumor tissue. we aim to determine these thresholds by collecting drs data on ex vivo brain and tumor samples. the tumor samples will be part of the normal extraction of tissue during tumor surgeries and the non tumorous tissue can be extracted in temporal/frontal lobe resections as well as epilepsy surgery, where non tumorous brain tissue is to be removed. the drs measurements are performed in direct connection to the extraction of tissue during surgery, and the tissue is thereafter sent to the pathologist according to standard clinical procedures. no extra tissue will need to be resected for the purpose of this study. based on the experiments we will propose a theoretical model for differentiating normal cerebral tissue from tumor tissue in humans for use during surgery.

Eligibility criteria:
inclusion criteria: * patients undergoing surgical resection of glial tumor or epileptic focus exclusion criteria: * unable to give informed consent
use of laparoscopy in the treatment of pelvic ring ruptures

Conditions: Pelvic Fracture

Summary: case series to describe the use of laparoscopy for the treatment of pelvic ring disruption.


Eligibility criteria:
inclusion criteria: * patients who underwent laparoscopy for the treatment of pelvic ring disruption exclusion criteria: * patient \< 18 years old

Keywords: pelvic ring surgery trauma surgery plate fixation laparoscopy case series
feasibility of telehealth palliative care and digital symptom monitoring for patients with acute myeloid leukemia

Conditions: Acute Myeloid Leukemia

Summary: aml is the most common leukemia diagnosed in adults. in spite of recent low-intensity therapies that have improved outcomes for older aml patients, aml remains associated with poor prognosis as well as high symptom burden. while the benefits of early palliative care as well as electronic pros have been well-described in the oncology population, neither have been well-studied in the aml population, and have never been studied in combination. we propose a prospective, single-center, single-arm trial to evaluate the feasibility of a virtually-mediated supportive care model utilizing both electronic pros and palliative care for patients with aml being treated with low-intensity therapy. aim1: is to evaluate and describe the feasibility of implementing early specialty palliative care referrals carried out via telehealth/video-based modalities in combination with digital symptom monitoring for patients recently diagnosed with acute myeloid leukemia (aml) and starting low intensity induction therapy. aim2: study the differences in health-related quality-of-life (hrqol) metrics using patient-reported outcomes (pros) in patients recently diagnosed with aml and starting low intensity induction therapy who receive early referral to telehealth/video-based palliative care visits compared to standard care. aim3: to explore the patient experience of patients with aml on low-intensity therapy, capture rates of advance care planning, hospice utilization, and hospital utilization.


Eligibility criteria:
inclusion criteria: * patients being treated for a diagnosis of acute myeloid leukemia at stanford cancer center * patients determined to be candidates for low intensity induction therapy (not requiring hospitalization to administer treatment) by their leukemia physician * estimated life expectancy of 6 months * functional status at the level of at least being capable of limited self-care, confined to chair or bed for half the day or better * access to smartphone, tablet, or computer with capability to utilize a symptom tracking application exclusion criteria: * relapsed or refractory aml * patients who have established care with palliative care previously * non-english-speaking, as the noona application is developed in the english language

Keywords: palliative care
merotocin in mothers with inadequate milk production and infants delivered prematurely

Conditions: Preterm Delivery; Inadequate Milk Production

Summary: induction and support of lactation in women with preterm delivery and inadequate milk production.


Eligibility criteria:
inclusion criteria: * delivered at the hospital system associated with the trial center * delivered preterm singleton gestational age 24 weeks + 0 days to 34 weeks + 2 days * willing to express milk at least 5 times every 24 hours during the observation period and 6 to 8 times every 24 hours during the treatment and post-treatment follow up * produced \< 200 ml milk in 24 hours prior to randomization * delivered 96 to 192 (+4) hours prior to randomization exclusion criteria: * pre-pregnancy body mass index (bmi) \> 50 kg/m\^2 * mastitis * history of breast trauma, breast surgery, nipple piercing * prolactin-releasing pituitary tumor, history of sheehan's syndrome, pituitary surgery/radiation therapy * pre-pregnancy insulin-dependent diabetes mellitus, polycystic ovarian syndrome. note: gestational diabetes is allowed (also when requiring the use of insulin for treatment) * unstable thyroid disease * moderate or severe renal or hepatic impairment * mental illness * significant nasal congestion or mucous production * use of anti-psychotic drugs within past 12 months

Keywords: inadequate milk production
reconstitution of a human immune system in a patient derived xenograft (pdx) model of genitourinary (gu) cancers

Conditions: Genito Urinary Cancer; Bladder Cancer; Kidney Cancer; Prostate Cancer

Summary: the objective of this study is to obtain human blood cd34+ hematopoietic stem/progenitor cells (hspcs) to reconstitute a match human immune system in our pdx model. the hypothesis is that by using matched leukocytes and pdx from the same patient, rejection of the pdx by the host immune system will not be observed and therefore a preclinical model to study immunotherapy can be developed to study, understand and improve upon our current therapies. hspcs will be collected from bone marrow aspirate obtained from a bone marrow biopsy. the secondary objective is to use patient tumor biopsy samples or circulating tumor cell samples to develop additional preclinical models of gu cancers, particularly prostate cancer, that are clinically relevant by generating additional pdxs.


Eligibility criteria:
inclusion criteria for bone marrow biopsy: 1. patients with genitourinary (gu) cancers and presence of existing patient derived xenograft or planned collection of tumor for pdx generation 2. age ≥ 18 years. 3. ability to understand and provide signed informed consent that fulfills institutional review board guidelines. 4. ability to undergo bone marrow biopsy 5. laboratory requirements (hematocrit 30%, platelets 75,000 + 10\^6/l and wbc 4000 x 10\^6/l) 6. karnofsky performance status \>70% exclusion criteria for bone marrow biopsy: 1. participants with serious concurrent chronic or acute illness that would affect the safety of a bone marrow biopsy. inclusion criteria for tumor biopsy 1. patients with prostate cancer a. biopsies in this study for diseases other than prostate cancer are not permitted. 2. age ≥ 18 years. 3. ability to understand and provide signed informed consent that fulfills institutional review board guidelines. 4. planned or willing to undergo a tumor biopsy. biopsies may be for research or clinical purposes depending on the treating provider for men with prostate cancer. biopsies in this study for diseases other than prostate cancer are not permitted 1. for research only biopsies: at least one lymph node or bone metastatic amenable to a minimum risk biopsy in the opinion of the treating physician. 2. for clinical purpose biopsies: there are no location or risk requirements. 5. laboratory requirements (hematocrit 30%, platelets 75,000 x 10\^6/l and wbc 4000 x 10\^6/l) 6. karnofsky performance status \>70% exclusion criteria for tumor biopsy: 1. participants with serious concurrent chronic or acute illness that would affect the safety of a tumor biopsy.
efficacy and safety of eslicarbazepine acetate as therapy for patients with post-herpetic neuralgia

Conditions: Postherpetic Neuralgia

Summary: the primary objective of the study is to assess the efficacy of eslicarbazepine acetate (esl) as therapy for patients with post-herpetic neuralgia.


Eligibility criteria:
inclusion criteria: * written informed consent to participate in the study * men and women aged 18 years or older * previous diagnosis of herpes zoster * diagnosis of postherpetic neuralgia and neuropathic pain present for more than 3 months after healing of the herpes zoster skin rash * cooperation and willingness to complete all aspects of the study * completion of at least 4 daily diaries during the week preceding randomisation * a minimum average daily pain score of 4 on the nrps in the last 4 diary entries before randomisation. exclusion criteria: * pain of other origin that might confound the assessment of neuropathic pain of postherpetic origin * active herpes zoster lesion or dermatitis of any origin at the affected site * subjects who had neurological ablation by block or neurosurgical intervention for control of pain * significant or unstable medical or psychiatric disorders * drug or alcohol abuse in the preceding 2 years * severe renal function impairment, as shown by calculated creatinine clearance values \< 30 ml/min at screening * relevant clinical laboratory abnormalities (e.g., na+ \ 2.0 times the upper limit of the normal, white blood cell count (wbc) \<2,500 cells/mm3) * previous participation in any study with eslicarbazepine acetate * pregnancy or breast feeding * history of hypersensitivity to the investigational products or to drugs with a similar chemical structure * history of non-compliance * likelihood of requiring treatment during the study period with drugs or other interventions not permitted by the clinical study protocol * participation in a clinical study within 3 months prior to screening * any clinical significant concomitant condition which might influence the assessments or conduct of the trial.

Keywords: pain herpetic neuralgia
analysis of the clinical experience with rucaparib in the rucaparib access program (rap) in spain - a geico study

Conditions: Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer

Summary: the study consists of a retrospective observational, multicenter study in which the fundamental exposure factor being investigated is a drug (rucaparib). a clinical database will be built including clinical data in three scenarios of rucaparib treatment: (1) platinum-sensitive brca-mutated patients after progression, (2) maintenance therapy in patients after a platinum-sensitive relapse in response, and (3) treatment therapy in brca-mutated patients who are currently platinum-resistant. the specific objectives of the study are: * to describe patient characteristics/medical history, safety, efficacy, and dosing of on-label treatment with rucaparib in real-world patients (real-world data). * to describe patient characteristics/medical history, safety, efficacy, and dosing of all patients treated with rucaparib (including patients with on-label treatment and others) in real-world patients (real-world data). * to show that data obtained in clinical trials could be reproduced in non-screened patients.


Eligibility criteria:
inclusion criteria: 1. written informed consent must be signed by all patients participating in the study who can be interviewed in the hospital (accessible, alive patients). informed consent may not be required from unaccessible patients (dead, lost, etc.) according to ethics committee permissions and applicable law for retrospective studies in spain. 2. histological diagnosis of high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer treated in the context of rucaparib access program (rap) in spain. 3. adult women (18 years or more at the time of diagnosis). exclusion criteria: 1. patients without medical record available (lost, empty or unretrievable clinical information).

Keywords: rucaparib
phase ii study of orelabrutinib combined with pd-1 inhibitor in relapsed/refractory primary central nervous system lymphoma

Conditions: Primary Central Nervous System Lymphoma

Summary: this is a prospective multicenter single-arm phase ii study, and the purpose of this study is to evaluate the efficiency of orelabrutinib combined with pd-1 inhibitor regimen relapsed/refractory primary intraocular lymphoma. overall response rate （orr） after 4 cycles is the primary endpoint.

all the patients will be treated with orelabrutinib combined with pd-1 inhibitor ：orelabrutinib 150mg qd，tislelizumab injection 200mg d1 or sintilimab injection 200mg d1， every 21-day for 1 cycle). patients will be evaluated every 2 cycles by mri scan during the first 6 cycles，and then the interval of investigation will be prolonged to 12 weeks. the patients who achieved complete remission (cr) or partial remission (pr) or stable disease (sd) will receive further treatment. the patients progressed disease (pd) will withdraw from the trial and receive salvage regimens. the treatment will be continued for 2 years or until progression of the disease (pd), unacceptable toxicity, or patient/investigator discretion. during following-up, surveillance ophthalmologic examination and brain magnetic resonance imaging (mri) scans can be performed every 3 months up for 2 years.

Eligibility criteria:
inclusion criteria: * age ≥18 years old ≤75 years old, male or female * primary central nerves system lymphoma confirmed by cytology or histology according to who2016 criteria * no evidence of systemic lymphoma * patients with a clear diagnosis of relapsed and/or refractory pcnsl: they received at least one regimen containing methotrexate. * at least one measurable lesion according to lugano 2014 criteria * adequate organ function and adequate bone marrow reserve exclusion criteria: * malignant tumors other than b-nhl within 5 years prior to screening, except cervical carcinoma in situ, basal cell or squamous cell skin cancer, local prostate cancer after radical surgery, and breast ductal carcinoma in situ after radical surgery * active hiv, hbv, hcv or treponema pallidum infection * any instability of systemic disease, including but not limited to active infection (except local infection), severe cardiac, liver, kidney, or metabolic disease need therapy * female subjects who have been pregnant or breastfeeding, or who plan to conceive during or within 1 year after treatment, or male subjects' partner plans to conceive within 1 year after their cell transfusion * active or uncontrolled infections requiring systemic treatment within 14 days before enrollment * any systemic antitumor therapy performed within 2 weeks before enrollment * previous use of other btk inhibitors or pd-1 inhibitors.

Keywords: primary central nervous system lymphoma orelabrutinib pd-1 inhibitor overall response rate
a study to learn more about how radium-223 is being used with other treatments in european patients who have not received radium-223 before

Conditions: Bone Metastatic Castration-resistant Prostate Cancer

Summary: in this study data from people with metastatic castration-resistant prostate cancer (mcrpc) with bone metastasis are studied. mcrpc is a prostate cancer which has spread to other parts of the body even when the amount of testosterone in the body was reduced. bone metastasis is when the cancer has spread to the bones. the study drug, radium-223, is currently available as a treatment for mcrpc with bone metastasis. but, its combination with certain other cancer treatments may lead to medical problems. therefore the instructions about how doctors should use radium-223 with other cancer treatments were changed. in this study, the researchers want to learn more about how doctors are now using radium-223 to treat patients with mcrpc and bone metastasis. the participants in this study will include men in denmark, germany, or the netherlands. they will not have received radium-223 before. they will have at least 6 months of medical records before starting treatment with radium-223. the researchers will collect the participants' medical records up to december 2020. the researchers will review information from the participants' medical records and medical claims from hospitals where the participants received radium-223. they will look at the medical records of participants who first started receiving radium-223 before there were new instructions about using it with other cancer treatments. they will also look at the medical records of participants who first started receiving radium-223 after there were new instructions. they will then count how many participants received other specific cancer treatments with radium-223. they will compare the results of the participants' who received radium-223 before the new instructions and those who received it after the new instructions. there are no required visits or tests in this study.


Eligibility criteria:
inclusion criteria: * patients who receive a first dispensing/administration of radium-223 during the before or after study period * patients who have at least 6 months of continuous enrolment in the study databases before the first dispensing/administration of radium-223 (to allow for evaluation of recent medical history and medication use) exclusion criteria: * patients who used radium-223 ever before the start of the before study period
studying dna in blood and bone marrow samples from younger patients with acute myeloid leukemia

Conditions: Adult Acute Myeloid Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission

Summary: this research trial studies deoxyribonucleic acid (dna) in blood or bone marrow samples from younger patients with acute myeloid leukemia. studying samples of blood and bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in dna and identify biomarkers related to cancer. it may also help doctors predict how well patients will respond to treatment.

primary objectives: l. perform a genome-wide scan to test for loci associated with acute myeloid leukemia (aml) relapse and infection risk. ii. validate positive associations seen in the genome-wide scan with a fine mapping approach. iii. perform simulated clinical trials using germline genetic variation data to test the feasibility of using genetic data to inform the clinical care of pediatric patients with aml. outline: germline dna is obtained from previously collected peripheral blood or bone marrow samples for array-based genotyping studies, including genome-wide association studies (single nucleotide polymorphisms) and fine mapping genotyping. clinical trial simulations are performed to test the clinical applicability of using genetic variation data in the management of infectious complications.

Eligibility criteria:
inclusion criteria: * diagnosis of aml * in remission * adequate dna from peripheral blood or bone marrow samples * concurrent enrollment on ccg-2961, cog-aaml03p1, cog-aaml0531, aml-93, aml-97, aml-04,aml-09, or canada aml infection clinical trial required
mhealth intervention to promote cancer survivors' physical activity

Conditions: Physical Activity; Quality of Life

Summary: the primary goal is to conduct a 5-10 week randomized controlled trial (rct) of the fitbit flex, a popular, affordable, wearable physical activity tracking device, and the fitbit mhealth app. the target population will be childhood cancer survivors 14-18 years old recruited from seattle children's hospital. for the intervention group, peer influences will be engaged via a private, social network (e.g. a facebook group) customized for survivors. measurements will be completed (1) at baseline, prior to randomization, and (2) during the final week of the intervention period (follow-up measure). this study will provide initial proof of concept and allow for further customization of the intervention for childhood cancer survivors in anticipation of a future, larger proposal to study physical activity and related outcomes over a multi-year period.


Eligibility criteria:
inclusion criteria: * in remission for childhood cancer and previously treated for childhood cancer at seattle children's hospital * ≥1-year post-cancer therapy * ambulatory without any known medical contraindications to participation * able to complete surveys in english * agree to install and share data from the fitbit smart phone app with the investigators exclusion criteria: * currently or previously used a wearable physical activity sensing device to improve physical activity
connective tissue matrix for rotator cuff tendinopathy

Conditions: Tendinopathy; Shoulder Pain; Rotator Cuff Tendinitis; Rotator Cuff Tendinosis

Summary: the purpose of this research study is to determine if the effectiveness of a single injection of ctm boost in the treatment of patients with rotator cuff tendinopathy (rct) is as effective as a single injection of platelet rich plasma (prp) in reducing the symptoms of rct.

rotator cuff tendinopathy (rct), is a chronic degenerative process which causes both shoulder pain as well as limited range of motion. it is currently estimated that approximately 5% of rct is being managed surgically, which highlights the importance of effective non-operative treatment strategies. the advent of platelet rich plasma (prp), a sample of blood drawn from a patient and concentrated to include mainly platelets and potent inflammatory mediators which promote healing, has shown promise as another treatment modality when injected at the site of tendon damage. placenta-derived decellularized connective tissue matrix (ctm) may represent an alternative therapy for rct. placenta-derived biologics can be administered as an injection and have been shown to promote tenocyte proliferation and to reduce inflammation in vitro, thus potentially accelerating and enhancing tendon healing. this study is being conducted to determine if injection of ctm boost is non-inferior to injection of prp with regard to pain and function at month 6 post-injection in patients with rotator cuff tendinopathy.

Eligibility criteria:
inclusion criteria: * patients aged 18-80 years old with rotator cuff tendinopathy * a prp or ctm-type injection was determined by the clinician to be the proper medical treatment course and patient is willing to undergo the injection exclusion criteria: * patients with adhesive capsulitis * patients with acromio-clavicular joint impingement, retracted tears, significant labral lesions or significant glenohumeral arthrosis * patients with joint instability * history of shoulder surgery or corticosteroid injection in the past 3 months * patients with any medical conditions that affect healing, such as end-stage renal disease or uncontrolled diabetes

Keywords: rotator cuff tendinopathy